For APIs, we are a partner of choice for international pharmaceutical companies
The active pharmaceutical ingredient (API) business is a key pillar of Dr. Reddy’s pharmaceutical operations. Starting from our journey as a bulk drug manufacturer in 1984, we have grown to be a leading developer, manufacturer and supplier of APIs globally. We leverage our scientific expertise and strong manufacturing capabilities for in-house formulations and to serve the needs of our customers.
We won the API Supplier of the Year Award at the Global Generics and Biosimilars Awards for three consecutive years in a row in 2019, 2020 and 2021.
Our offerings
We use Quality by Design techniques to produce complex molecules enabling customers to create successful formulations. Our 8 global manufacturing units run in accordance with Current Good Manufacturing Practices (cGMP) and have been successfully audited by international regulatory bodies such as the US Food and Drug Association (FDA).
Our supply chain is resilient, supported by strategic sourcing partnerships. We provide excellent customer service through a dedicated team of quality, regulatory, and commercial experts. As a member of the Pharmaceutical Supply Chain Initiative, we are committed to sustainable supply chain practices based on the principles of ethics, human rights and labour, health and safety, environment, and management systems. We strive to bring complex products and enable launches ahead of others at competitive prices. We offer niche capabilities and technology platforms at competitive cost structures to innovator and biotechnology companies.
Growing base
We plan to grow the API business by launching new products through backward integration into core molecules, and by boosting our business in key geographies. In FY2024, we filed 133 drug master files (DMFs) globally, of which 11 were in the U.S. Cumulatively, our total active DMFs filed worldwide as of March 31, 2024 were 1,861, including 251 active DMFs filed in the U.S. We have an equally strong pipeline of products.
We have also moved up the chain from providing simple APIs to supplying value-added APIs to our institutional customers in over 25 countries, and intend to expand this product basket to over 60 countries (June ’23).
We utilize flow chemistry for hazardous and cryogenic reactions. The driver to adopt this is a move towards sustainable manufacturing with improved green metrics, lower operating costs, and minimal manual operations. We are also in the process of commissioning a modular plant for an intermediate to API process encompassing multiple reactions and unit operations.
For several international pharmaceutical companies, we are a partner of choice for APIs and will continue to maintain our leadership through new product offerings, cost competencies, and high service standards.
For more information, please visit: api.drreddys.com
